Esperion Theraptc (ESPR)

Feb 18, 2025, 8:00 AM EST - 4 days ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Feb 13, 2025, 4:30 PM EST - 9 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 18, 2024, 7:00 AM EST - 2 months ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 2 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 2 months ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 2 months ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 2 months ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 3 months ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 3 months ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 3 months ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 3 months ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 4 months ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 5 months ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Sep 3, 2024, 8:00 AM EDT - 6 months ago

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

Aug 26, 2024, 8:00 AM EDT - 6 months ago

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 9:10 AM EDT - 6 months ago

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs

Aug 16, 2024, 4:09 AM EDT - 6 months ago

Esperion Therapeutics: Strategically Positioned To Grow

Aug 12, 2024, 9:50 PM EDT - 6 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 6:00 AM EDT - 6 months ago

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jul 16, 2024, 8:00 AM EDT - 7 months ago

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

Jun 28, 2024, 7:00 AM EDT - 8 months ago

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

May 23, 2024, 9:00 AM EDT - 9 months ago

Esperion to Participate in Upcoming June Investor Conferences

May 20, 2024, 6:00 AM EDT - 9 months ago

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

May 20, 2024, 5:43 AM EDT - 9 months ago

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 14, 2024, 8:00 AM EDT - 10 months ago

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

May 7, 2024, 10:05 AM EDT - 10 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript

May 7, 2024, 6:00 AM EDT - 10 months ago

Esperion Reports First Quarter 2024 Financial Results

Apr 29, 2024, 8:00 AM EDT - 10 months ago

Esperion to Participate in Upcoming May Investor Conferences

Apr 7, 2024, 2:45 PM EDT - 11 months ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Apr 1, 2024, 12:48 PM EDT - 11 months ago

Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications

Apr 1, 2024, 8:00 AM EDT - 11 months ago

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Mar 26, 2024, 8:00 AM EDT - 11 months ago

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Mar 25, 2024, 4:00 PM EDT - 11 months ago

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

Mar 22, 2024, 6:26 PM EDT - 1 year ago

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Mar 22, 2024, 3:10 PM EDT - 1 year ago

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Mar 22, 2024, 11:04 AM EDT - 1 year ago

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

Feb 28, 2024, 3:13 PM EST - 1 year ago

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 27, 2024, 11:18 AM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

Feb 1, 2024, 2:00 PM EST - 1 year ago

RFK, Esperion Therapeutics Announce 2024 Promotional Schedule

Jan 25, 2024, 3:57 PM EST - 1 year ago

This late-January stock-trading pattern has been a winner in 30 of the past 38 years

DIS QQQ SPY TLT UNM XLP

Jan 23, 2024, 4:00 PM EST - 1 year ago

Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Jan 22, 2024, 5:13 PM EST - 1 year ago

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 18, 2024, 9:15 PM EST - 1 year ago

Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock

Jan 18, 2024, 4:00 PM EST - 1 year ago

Esperion Announces Proposed Public Offering of Common Stock

Jan 14, 2024, 9:00 AM EST - 1 year ago

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 3, 2024, 7:00 AM EST - 1 year ago

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

Dec 13, 2023, 4:00 PM EST - 1 year ago

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet